The pooled analysis showed inconclusive effects on CD8+ between the CHM and control treatment groups among COVID-19 patients, of which, the combined SMD of CD8+ was 0.47 (95% CI, −0.30–1.23, P = 0.23; random effect model) (Figure 2C). Here, CD8A is linked to COVID-19.